tagrisso
astrazeneca ab - osimertinib mesilate - karsinooma, ei-pienisoluinen keuhko - muut antineoplastiset aineet, proteiinikinaasin estäjät - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
mutagrip 15 mikrog ha / 0.5 ml injektioneste, suspensio
sanofi pasteur msd - influenssa a-viruksen h1n1, virusfragmentit, inaktivoitu,influenssa a-viruksen h3n2, virusfragmentit, inaktivoitu,influenssa b virus, virusfragmentit, inaktivoitu - injektioneste, suspensio - 15 mikrog ha / 0.5 ml - influenssarokote, puhdistettu antigeeni
uniferon 200 mg/ml injektioneste, liuos
pharmacosmos a/s - iron dextran complex - injektioneste, liuos - 200 mg/ml - rauta
ursoferran 200 mg/ml injektioneste, liuos
serumwerk bernburg ag - gleptoferron - injektioneste, liuos - 200 mg/ml - rauta
denagard vet 450 mg/g rakeet
elanco gmbh - tiamulini hydrogenofumaras - rakeet - 450 mg/g - tiamuliini
ketovet vet 100 mg/ml injektioneste, liuos
vetviva richter gmbh - ketoprofen - injektioneste, liuos - 100 mg/ml - ketoprofeeni